Skip to content

Insider · CIK 0001435744

Thomas DesRosier

officer

Files at MCRB (Seres Therapeutics, Inc.). First filing Oct 29, 2024, latest Aug 19, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 5
$0 bought, $8,740 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

MCRB: Seres Therapeutics, Inc.

MCRBOct 9, 2026 · close 2.71

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
0Weak
MCRBsell 410b5-1
Seres Therapeutics, Inc.
$1,265
76 shares
-1%+161% from low-24% from high
0Weak
MCRBsell 410b5-1
Seres Therapeutics, Inc.
$575
79 shares
-1%+9% from low-68% from high
0Weak
MCRBsell 210b5-1
Seres Therapeutics, Inc.
$3,485
4,300 shares
-3%-
0Weak
MCRBsell 510b5-1
Seres Therapeutics, Inc.
$475
878 shares
-1%-
0Weak
MCRBsell 510b5-1
Seres Therapeutics, Inc.
$2,939
4,259 shares
-3%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Aug 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+133--7,420Aug 19, 2025
Aug 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+111--7,531Aug 19, 2025
Aug 18, 2025MCRB
Seres Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-76$16.65$1,2657,455Aug 19, 2025
Aug 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-133$0.00$0796Aug 19, 2025
Aug 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-111$0.00$01,113Aug 19, 2025
May 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+133--7,255May 19, 2025
May 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+111--7,366May 19, 2025
May 15, 2025MCRB
Seres Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-79$7.28$5757,287May 19, 2025
May 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-133$0.00$0929May 19, 2025
May 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-111$0.00$01,224May 19, 2025
Feb 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+2,657--137,849Feb 19, 2025
Feb 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+8,907--146,756Feb 19, 2025
Feb 18, 2025MCRB
Seres Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-4,300$0.81$3,485142,456Feb 19, 2025
Feb 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-2,657$0.00$021,250Feb 19, 2025
Feb 15, 2025MCRB
Seres Therapeutics, Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-8,907$0.00$026,718Feb 19, 2025
Feb 7, 2025MCRB
Seres Therapeutics, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+650,000$0.00$0650,000Feb 11, 2025
Nov 15, 2024MCRB
Seres Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+2,656--136,070Nov 19, 2024
Nov 18, 2024MCRB
Seres Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-878$0.54$475135,192Nov 19, 2024
Nov 15, 2024MCRB
Seres Therapeutics, Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-2,656$0.00$023,907Nov 19, 2024
Oct 27, 2024MCRB
Seres Therapeutics, Inc.
MOption exercise
Common Stock10b5-1
+13,500$0.00$0137,673Oct 29, 2024
Oct 28, 2024MCRB
Seres Therapeutics, Inc.
SOpen-market sale
Common Stock10b5-1
-4,259$0.69$2,939133,414Oct 29, 2024
Oct 27, 2024MCRB
Seres Therapeutics, Inc.
MOption exercise
Restricted Stock Unitsderivative10b5-1
-13,500$0.00$00Oct 29, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Thomas DesRosier: insider trades and track record | InsiderTell